AllSight
Companies · SEPN · Pharmaceutical Preparations

Septerna, Inc. (SEPN)

Septerna, Inc. (SEPN) stock — the fundamentals (P/E, market cap, valuation) and every material event, decoded in plain English.

Septerna, Inc. (SEPN) stock — financials & valuation

Key numbers for Septerna, Inc. (SEPN): P/E ratio, market cap, profit margins, returns, and whether the stock looks cheap or expensive versus its own 5-year range.

AllSight quality score: 51/100 — a percentile rank of Septerna, Inc.’s fundamentals against Manufacturing peers, weakest on management. A quality ranking, not a price prediction.

Market cap$1.8B
P / S18.0×
EV / EBITDA-31.1×
Gross margin100.0%
Operating margin-56.7%
Net margin-24.5%
Return on equity-6.3%
ROIC-19.6%
Debt / equity0.0×
Dividend yield0.0%

Independent of the events above — derived from Septerna, Inc.’s own financial statements and shown as context, never as advice.

Aug 25, 2026CMO appointed
Septerna names Rajiv Patni chief medical officer, but offers no pipeline update
Aug 10, 2026
Strong financial beat, but key clinical catalysts move later
Related companies in Pharmaceutical Preparations
Open live on AllSight — the whole market, decoded →

About AllSight · Editorial standards & method · Contact